5 Live - Major conference takeways from experts in 5 minutes or less. Featuring new content from #ASCO20
-
Roy Herbst, MD, PhD, FACP, FASCO; Yale Cancer Center 5Live #ASCO20
4:24
Key insights on Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
-
Ajay K. Nooka, MD, MPH, FACP; Emory Winship Cancer Institute 5Live #ASCO20
4:59
Key Insights on DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
-
Hope S. Rugo Professor of Medicine; Director, Breast Oncology and Clinical Trials Education; UCSF Comprehensive Cancer Center 5Live #ASCO20
6:58
"Key Insights on Alpelisib + fulvestrant in PIK3CA-mutated HR+/HER2– advanced BC previously treated with CDK 4/6 inhibitor + aromatase inhibitor (AI): BYLieve study results "
-
Lindsey Roeker, MD Memorial Sloan-Kettering Cancer Center 5Live #ASCO20
3:55
Key Insights on Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results
-
Thomas Powles, MD, MRCP; Barts Cancer Center 5Live #ASCO20
2:50
Key insights on IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
-
David Siegel, MD, PhD
4:13
Summary of CAR T-cell Therapy. Updates from ASH 2019.
-
Andrew Evens, DO, MSc, FACP
6:16
Summary of Hodgkin lymphoma updates from SOHO 2019.
-
Charles Herbaux, MD, MSc Centre Hospitalier Regional Universitaire de Lille, France 5Live #ASCO20
5:36
Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
-
Paolo Strati, MD; University of Texas MD Anderson Cancer Center 5Live #ASCO20
5:45
Key insights on Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).
LEAD: Leadership, Empowerment and Development for Women in Oncology
-
Nina Shah, MD, Julie Vose, MD, MBA, and Julie Brahmer, MD, MSc
2:27
LEAD 2019 key highlights from the conference Co-Chairs
-
Debra Patt, MD, MPH, MBA
1:28
Summary of Session VI: Patient Management and Supportive Care in an Era of New Therapies from LEAD 2019
-
Lauren Byers, MD and Joyce O'Shaughnessy, MD
12:37
Key Highlights on Emerging Biomarkers Session
-
Shikha Jain, MD, FACP and Stephanie Graff, MD
12:38
Social Media Workshop Key Highlights
-
Linda Bosserman, MD, Jane Meisel, MD, and Leora Horn, MD, MSc, FRCPC
6:31
Summary of Session VII: Workshop Panel on Leaning Into Leadership Opportunities from LEAD 2019
-
Stephanie Graff, MD and Charu Aggarwal, MD, MPH
3:49
Summary of Session VII: Workshop Panel on Building Your Brand from LEAD 2019
-
Sandra Horning, MD
1:15
Key highlights from the LEAD 2019 conference
-
Barrett McBride, Rachna Shroff, MD, and Elizabeth Comen, MD
14:48
Resiliency Workshop Key Highlights
-
Alessandra Ferrajoli, MD & Arlene Siefker-Radtke, MD
10:37
Key Clinical Highlights in CLL and Bladder Cancer
